Читать книгу Diagnóstico y tratamiento de la infección por el virus de la inmunodeficiencia humana, Infecciones oportunistas y trastornos relacionados - Rosa Nohemí Terán Terán - Страница 18

BIBLIOGRAFÍA

1.Wilcox M. Evaluation of the HIV-infected patient with hepatobiliary complaints. UpToDate.

2.Neukam K, Mira J, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A. Liver toxicity associated with antiretroviral therapy incluiding efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients. J Antimicrob Chemother. 2011; 66(11): p. 2605-14.

3.DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents - A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. AIDSinfo. 2019: p. 1-21.

4.Neukam K, Mira J, Collado A, Rivero-Juárez A, Torres-Cornejo A. Liver toxicity of current antiretroviral regimens in HIV-infected patients with chronic viral hepatitis in a real-life setting The HEPAVIR SEG- HEP Cohort. PLoS One. 2016; 11(2): p. 1-12.

5.Panel de expertos de GeSIDA y Plan Nacional sobre el sida. Documento de consenso de Gesida/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia human (actualización enero 2019). 2019.

6.Song I, Borland J, Savina P, Chen S, Patel P, Wajima T. Pharmacokinetics of Single-Dose Dolutegravir in HIV-Seronegative Subjects With Moderate Hepatic Impairment Compared to Healthy Matched Controls. Clin Pharmacol Drug Dev. 2013; 2(4): p. 342-8.

7.Hernández-Novoa B, Pérez-Elías M, Quereda C, Dronda F, Casado J, Madrid E. Raltegravir pharmacokinetics in HIV-HCV-coinfected patients with advanced liver cirrhosis. Journal of Antimicrobial Chemotherapy Oxford Academic. 2013; 69(2): p. 471-5.

8.Gallant J, Brunetta J, Crofoot G, Benson P, Mills A, Brinson C. Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) in HIV-1/Hepatitis B Coinfected Adults. J Acquir Immune Defic Syndr. 2016; 73(3): p. 1.

9.Law W, Dore C, Duncombe C, Mahanontharit A, Boyd M, Ruxrungtham K. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV - NAT Cohort Thailand 1996-2001. AIDS. 2003; 17(15): p. 2191-9.